Stille AB (STIL) AI Stock Analysis

0 Followers

Stille AB

(Nasdaq OMX AB:STIL)

Select Model

Rating:74Outperform

Price Target:SEK 281.00▲(7.66% Upside)

Action:reiterated

Date:10/27/26

Stille AB's overall score of 74 reflects a company in excellent financial health with a debt-free balance sheet and rapidly improving cash flows. The strongly positive earnings call, highlighting record sales and margin expansion, reinforces the positive outlook. However, the score is moderated by neutral technical momentum and a fair but not compelling valuation, with growth expectations already partially priced in.

Positive Factors

Revenue and Profitability GrowthStrong organic growth is being accompanied by faster EBITDA expansion, indicating operating leverage rather than growth purchased solely through higher costs. If sustained, this combination can strengthen earnings power, fund commercial investment, and support continued competitive progress over the next several quarters.

Negative Factors

Backorders and Supply NormalizationPersistently elevated backorders can delay customer deliveries, defer revenue recognition, and constrain the company's ability to convert strong underlying demand into repeatable sales. Continued investment may improve service, but normalization remains necessary for execution and customer experience.

Stille AB (STIL) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 2.27B
Dividend Yield: ―
Average Volume (3M): 9,438
Price to Earnings (P/E): 23.6
Beta (1Y): 0.26
Revenue Growth: 28.75%
EPS Growth: 138.25%
Country: Sweden
Employees: 225
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Stille AB Business Overview & Revenue Model

Company Description

Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut...

How the Company Makes Money

Stille makes money primarily by selling medical technology products to healthcare providers and related procurement channels. Key revenue streams include: (1) Sales of surgical instruments: revenue generated from manufacturing and supplying reusable...

Stille AB Earnings Call Summary

Earnings Call Date:Oct 23, 2026(Q3-2026)|% Change Since:-2.61%|Next Earnings Date:Feb 12, 2027

Earnings Call SentimentPositive

The call was strongly positive, with record rolling 12-month sales, robust organic growth, improved margins, sharply higher operating cash flow, stronger delivery performance, and a net cash position. The main challenges were elevated backorders, currency-related pressure on Surgical Instruments margins, partially outstanding tariff refunds, and management's caution that the exceptional 30% Surgical Tables growth rate is not expected to continue at the same level.

Positive Updates

Strong Q3 Revenue Growth

Q3 revenue increased to SEK 170.6 million, up 22.9% year over year, with organic growth of 16.5%. Currency translation contributed SEK 2.1 million, resulting in total growth of 21.5% and organic growth of 15.2% in constant currencies.

Negative Updates

Backorders Remain Elevated

Although backorder levels were reduced during Q3 and further reduction is expected in Q4, management stated that elevated backorder levels remain and that the supply situation is not fully back to normal.

Company Guidance

Management reiterated its long-term guidance to deliver +10% organic growth, an EBITDA margin of 25% and leverage of less than 3x net debt/EBITDA; it expects a gradual decrease in backorder level and a further reduction during Q4. Management said instrument-market growth is more a mid-single-digit growth and that +10% organic growth is a realistic target, while table sales growth of around 30% versus 2025 is clearly not a growth you should just extrapolate going into 2027 and 30% next year might be a stretch; no specific outlooks on individual segments, nor year by year outlook, were provided. Management’s target is to recover more tariff refunds, with the SEK 5.2 million received estimated at around 60% of what it would expect to see.

Stille AB Financial Statement Overview

Summary

Stille AB demonstrates strong financial health with accelerating TTM revenue growth of 4.7%, expanding net profit margins to 13.5%, and a debt-free balance sheet. Cash flow generation has improved dramatically, with TTM operating cash flow more than doubling. The main weakness is historical revenue volatility.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	711.42M	567.63M	569.95M	294.89M	246.35M	187.09M
Gross Profit	352.93M	287.97M	295.64M	132.17M	111.57M	83.46M
EBITDA	143.34M	109.01M	129.50M	56.04M	44.78M	28.89M
Net Income	96.27M	55.70M	58.21M	26.65M	27.32M	16.10M
Balance Sheet
Total Assets	1.17B	1.05B	1.00B	804.89M	342.55M	308.85M
Cash, Cash Equivalents and Short-Term Investments	170.71M	118.66M	158.49M	241.45M	36.68M	27.80M
Total Debt	0	123.26M	63.09M	62.94M	70.77M	81.48M
Total Liabilities	360.44M	345.54M	301.70M	172.64M	152.74M	160.75M
Stockholders Equity	809.76M	708.71M	699.40M	632.25M	189.81M	148.10M
Cash Flow
Free Cash Flow	64.22M	15.46M	59.24M	24.37M	23.89M	-11.74M
Operating Cash Flow	87.80M	36.05M	73.53M	37.28M	31.94M	7.28M
Investing Cash Flow	-33.88M	-104.30M	-330.31M	-12.90M	-8.04M	-51.90M
Financing Cash Flow	-25.45M	36.16M	171.40M	178.99M	-18.54M	33.22M

Stille AB Technical Analysis

Technical Analysis SentimentPositive

Last Price261.00

Price Trends

50DMA247.99Positive

100DMA244.93Positive

200DMA231.14Positive

Market Momentum

MACD1.04Positive

RSI51.65Neutral

STOCH76.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Positive. The current price of 261.00 is above the 20-day moving average (MA) of 253.80, above the 50-day MA of 247.99, and above the 200-day MA of 231.14, indicating a neutral trend. The MACD of 1.04 indicates Positive momentum. The RSI at 51.65 is Neutral, neither overbought nor oversold. The STOCH value of 76.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:STIL.

Stille AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:STIL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:BONEX	81Outperform	SEK 20.71B	77.58	29.00%	―	25.20%	79.34%
SE:STIL	74Outperform	SEK 2.29B	23.60	―	―	28.75%	138.25%
SE:ALIF.B	74Outperform	SEK 22.20B	34.90	11.32%	0.82%	1.62%	63.45%
SE:SUS	73Outperform	SEK 3.09B	34.07	―	―	8.40%	0.74%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:OSSD	45Neutral	SEK 413.19M	-8.10	―	―	-11.89%	-11.85%
SE:FLUO	41Neutral	SEK 480.67M	-6.51	―	―	―	-23.57%

* General Sector Average

Performance Comparison

SE:STIL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:STIL	Stille AB	261.00	86.50	49.57%
SE:ALIF.B	AddLife AB Class B	181.70	-1.89	-1.03%
SE:BONEX	BONESUPPORT HOLDING AB	316.80	109.40	52.75%
SE:SUS	Surgical Science Sweden AB	55.60	-17.40	-23.84%
SE:OSSD	OssDsign AB	3.50	-7.50	-68.18%
SE:FLUO	FluoGuide A/S	29.20	-13.50	-31.62%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Stille AB AI Stock Analysis